Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer

Fig. 2

a Kaplan-Meier curve of overall survival. b Forest plot of subgroup analysis of overall survival Median OS follow-up time was estimated by the reverse Kaplan-Meier method with 95% Cis estimated using the Brookmeyer-Crowley method. The median duration of follow-up for overall survival was 20.47 months (IQR, 18.33–22.18 months) for the socazolimab plus EC group and 20.63 months (IQR, 19.78–21.49 months) for the placebo plus EC group. *Calculated using a 2-sided stratified log-rank test

Back to article page